RZLT
Rezolute, Inc. [RZLT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RZLT Stock Summary
Top 10 Correlated ETFs
RZLT
Top 10 Correlated Stocks
RZLT
In the News
RZLT Financial details
Company Rating
-
Market Cap
106.99M
Income
-56.85M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
57
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.03
Forward P/E
-
PEG
0.22
P/S
-
P/B
0.56
P/C
-
P/FCF
-0.94
Quick Ratio
13.72
Current Ratio
14.27
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.11
EPS next Y
-
EPS next Q
-
EPS this Y
-52.58%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-3.57%
-
-
-
-
SMA20
3.29%
SMA50
41.23%
SMA100
117.05%
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
-46%
ROC
-0.58%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.72-2.7492
52W High
-
52W Low
-
RSI
52.08
Rel Volume
3.87
Avg Volume
326.82K
Volume
1.26M
Perf Week
0.89%
Perf Month
11.79%
Perf Quarter
147.96%
Perf Half Y
120.87%
-
-
-
-
Beta
1.325
-
-
Volatility
0.22%, 0.42%
Prev Close
-2.36%
Price
9.1
Change
-6.76%
Company Profile
- Volume Average 326.82K
- Market Capitalization 106.99M
- Employee 57
- CEO Mr. Nevan Charles Elam J.D.
- Headquarters Redwood City,CA,US
- IPO Date 2013-01-14
-
Website
https://www.rezolutebio.com 
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
